News & Updates

Among nondiabetic patients with first-onset ST-elevation myocardial infarction (STEMI), stress hyperglycaemia is more likely to occur in older patients but is associated with the greatest risk of mortality in younger patients, according to local research.

Chronic obstructive pulmonary disease (COPD) is increasingly recognized to be closely linked to cardiovascular-kidney-metabolic (CKM) conditions. As the population ages, patients with multiple comorbidities, including CKM syndrome and COPD, are commonly encountered in clinical practice across multiple specialties. A more coordinated effort and enhanced awareness are required for better management and outcome. At a symposium organized by the Federation of Medical Societies of Hong Kong (FMSHK) chaired by Dr Samuel Ka-Shun Fung, Executive Committee Member of FMSHK, Dr Ka-Chun Leung, Specialist in Nephrology of Tuen Mun Hospital, Dr Emmanuel Chun-Ka Wong of the Division of Cardiology, University of Hong Kong, and Dr Fanny Wai-San Ko of the Division of Respiratory Medicine, the Chinese University of Hong Kong, discussed how evolving multiorgan dysfunction, overlapping clinical presentations, and sequential treatment decisions shape diagnosis and management of these conditions. A case discussion of progression from chronic kidney disease (CKD) to worsening COPD and, subsequently, heart failure (HF) highlighted diagnostic and therapeutic complexities, and provided practice insights.

Obstructive sleep apnoea (OSA) contributes to an increased risk of cardiovascular disease (CVD) events for patients with cancer, and this risk increase persists regardless of obesity status and is more pronounced in women, according to a retrospective study.

In the treatment of patients with systemic lupus erythematosus, anifrolumab is associated with reduced cardiovascular disease (CVD) risk compared with belimumab, as shown in a retrospective study.

In patients with serious mental illness (SMI), initiation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with lower risks of all-cause mortality and major adverse cardiovascular events (MACEs) vs sodium-glucose cotransporter-2 (SGLT2) inhibitors, a large study has shown.

New drug applications approved by US FDA as of 1-15 December 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

New drug applications approved by US FDA as of 16-31 July 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

The risk of atherosclerotic cardiovascular disease (ASCVD) events increases by more than fourfold in the presence of polyendocrine metabolic ovarian syndrome (PMOS), according to a retrospective study from the US.